Dr. Emanuela Argilli's research lab at UCSF focuses on understanding the genetic causes of agenesis of the corpus callosum (ACC), a brain condition linked to various neurodevelopmental disorders like autism, epilepsy, and intellectual disabilities. By studying genetic data from large population samples and engaging in cutting-edge genomic techniques, the lab aims to discover novel genes associated with ACC and explore their implications for brain function and potential treatments. Ultimately, this research could lead to better understanding and interventions for common developmental disorders affecting many individuals worldwide.

Dr. Jet M.J. Vonk's research lab at UCSF focuses on utilizing automated speech analysis to detect early signs of Alzheimer's disease (AD). The lab aims to develop and validate a speech profile that captures subtle language changes indicative of cognitive decline, especially in racially and ethnically diverse populations. By employing machine learning techniques on speech samples, the lab seeks to create a clinically viable tool for early diagnosis and monitoring of AD, bridging gaps in current diagnostic practices.

Dr. Joshua D. Berke's research lab at UCSF focuses on the brain's reward signaling systems, particularly how dopamine affects motivation and learning. By studying the nucleus accumbens, a key area for processing rewards, the lab aims to unravel the complexities of how dopamine signals influence behavior, decision-making, and learning in both animals and by extension, humans. The work also explores the role of the hippocampus in guiding intelligent choices based on past rewards and future possibilities.

Dr. Adam L. Boxer leads a research lab focusing on Progressive Supranuclear Palsy (PSP), a fatal neurodegenerative disease with no effective treatments. His lab aims to evaluate the safety and efficacy of multiple new therapies in PSP patients through efficient clinical trials that can expedite access to promising treatments. Using advanced diagnostic tools and collaborative platforms, the lab seeks to develop new biomarkers and therapeutic strategies to improve patient outcomes.

Dr. Daniele Canzio's lab at UCSF focuses on understanding how the genome's structure affects brain development and function. By studying specific cell-surface proteins, the lab investigates how neurons recognize and avoid self-damage during their growth and wiring. This research not only sheds light on normal brain development but is also key to understanding disorders related to neural connectivity.

Dr. Marta San Luciano's lab focuses on developing innovative treatment strategies for children and young adults with cerebral palsy (CP), particularly through the use of cerebellar deep brain stimulation (DBS). This research aims to improve movement disabilities and muscle tightness associated with CP by targeting the cerebellum, a brain region that often remains intact in these patients. The lab combines advanced neurotechnology with clinical assessments and brain imaging to enhance the quality of life for individuals suffering from movement disorders related to CP.

Dr. Christine K. Fox's lab at the University of California, San Francisco focuses on understanding the complex link between childhood stroke, seizures, and the development of epilepsy. Her research aims to uncover the inflammatory processes and brain regions involved in these occurrences, using data from children who have experienced strokes. The ultimate goal is to improve recovery outcomes and find effective treatments for preventing epilepsy in young stroke patients.

Dr. Claire Clelland's lab at UCSF focuses on innovative approaches to address neurological diseases through advanced gene therapy techniques. They develop and test new methods to deliver treatments directly to the central nervous system (CNS) using ethically sourced human cadaver models. Additionally, their work involves utilizing CRISPR technology to target and edit genes associated with conditions like frontotemporal dementia, aiming to create effective therapeutic options for patients.

Dr. Peter Alexander Ljubenkov's lab focuses on finding new treatments for patients with semantic variant primary progressive aphasia (svPPA), a form of dementia closely linked to frontotemporal lobar degeneration. They are conducting a clinical trial to test a drug called Verdiperstat, which may help address the underlying causes of this condition. The lab aims to gather important information about how the drug works and its safety in patients, contributing to future therapies for cognitive disorders related to neurodegeneration.

Dr. Maria Luisa Gorno Tempini's research focuses on improving the diagnosis and monitoring of Alzheimer's disease and frontotemporal dementia, particularly among Latino and English-speaking populations. Using innovative automated speech and language analysis techniques, her lab aims to identify specific markers of cognitive decline across diverse socio-biological backgrounds. This research not only addresses the inequities in dementia assessment but also strives to develop cost-effective, culturally sensitive diagnostic tools that can benefit underrepresented communities.

Dr. Felicia C. Chow's lab focuses on understanding how sexual differences influence neurocognitive impairment and recovery in people living with HIV, alongside improving diagnostic methods for tuberculous meningitis. By studying the impacts of cerebrovascular health and immune responses, her research aims to develop better treatments tailored to men and women. Moreover, her lab is dedicated to enhancing research capacity in regions heavily affected by tuberculosis, fostering local expertise for more effective health interventions.

Dr. Hannah Cranley Glass's research lab at UCSF focuses on understanding the genetic factors that influence the development of epilepsy in children who have experienced neonatal seizures. By studying a diverse cohort of children, the lab aims to identify genetic changes linked to the increased risk of epilepsy after brain injury. Their work seeks to improve prediction methods for epilepsy risk and refine treatment approaches for affected children, ultimately contributing to better health outcomes for vulnerable populations.

Dr. Yvonne W. Wu leads research aimed at improving fetal monitoring techniques to prevent neonatal brain injuries. Her lab focuses on analyzing electronic fetal monitoring data to better predict the risk of conditions like hypoxic-ischemic encephalopathy (HIE), which can lead to serious long-term disabilities in newborns. Through advanced data analysis and machine learning methods, her research seeks to enhance clinical outcomes for infants during labor and delivery.

Dr. Heather J. Fullerton's lab focuses on understanding the disease process and treatment options for a condition called focal cerebral arteriopathy (FCA), which is a leading cause of strokes in children. The lab is conducting a clinical trial (FOCAS) to compare two treatment strategies using corticosteroids to see which one leads to better health outcomes for affected children. They aim to ensure that children receiving treatment have the best chance of recovery and improvement in their neurological health.

Dr. Yin Shen's lab at UCSF focuses on understanding the genetic factors that contribute to Alzheimer's disease, specifically how risk genes and their variants influence gene expression and related biological functions. The lab uses advanced techniques such as CRISPR and single-cell analysis to study the interactions between these genetic factors and the disease. By examining nerve cells and brain organoids, the lab aims to uncover new insights that could lead to better risk predictions and therapeutic targets for Alzheimer's disease.

Dr. Corey C. Harwell's lab focuses on understanding the development and function of specific neurons in the septal complex of the brain, which plays a key role in social behavior and emotional regulation. The lab investigates how early life exposure to opioids can lead to long-term changes in brain function and contribute to neuropsychiatric disorders. By analyzing the molecular pathways and cellular adaptations in these neurons, the research aims to uncover potential therapeutic targets for treating conditions like anxiety and depression.

Dr. Stephen L. Hauser's lab at UCSF focuses on understanding the role of B cells in multiple sclerosis (MS), a debilitating autoimmune disease of the central nervous system. The team investigates how B cells contribute to the onset and progression of MS by studying samples from patients at different stages of the disease. They combine advanced imaging techniques, genetic analysis, and innovative antibody technologies to uncover the mechanisms that trigger MS and influence its progression, aiming to improve therapeutic strategies for patients.

Aimee Kao's research lab focuses on understanding the role of lysosomes in neurodegenerative diseases such as Alzheimer's and frontotemporal dementia. The lab studies how specific protein fragments, known as PGRN species, influence the degradation of a harmful protein called TDP-43, especially as people age. By exploring these mechanisms, the lab aims to identify potential new treatments for these age-related disorders.

Dr. Joel H. Kramer and his lab at UCSF focus on understanding small vessel cerebrovascular disease, particularly how it contributes to cognitive decline in older adults. They aim to identify reliable markers that can help detect and monitor this disease early on, improving how we diagnose and treat affected patients. By following a diverse group of older individuals showing signs of cerebrovascular issues, they are working to validate new neuroimaging and fluid-based biomarkers that could greatly enhance clinical trials and patient care.

Dr. Bruce L. Miller's research lab at UCSF focuses on understanding and addressing dementia in Latino populations, a group that has been historically underrepresented in dementia research. Through a multi-partner consortium, the lab investigates the effects of socioeconomic factors, genetic variants, and brain aging on Alzheimer's disease and frontotemporal lobar degeneration. By gathering data from participants across Latin America and the United States, the lab aims to develop culturally tailored interventions to improve dementia care and outcomes.